Genelux Files Routine 8-K, Confirms Nasdaq Listing

Ticker: GNLX · Form: 8-K · Filed: Feb 5, 2024 · CIK: 1231457

Genelux Corp 8-K Filing Summary
FieldDetail
CompanyGenelux Corp (GNLX)
Form Type8-K
Filed DateFeb 5, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, compliance

TL;DR

**Genelux filed a routine 8-K, no major news, just standard compliance.**

AI Summary

Genelux Corporation filed an 8-K on February 5, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on The Nasdaq Stock Market LLC under the trading symbol GNLX. This filing doesn't contain new financial results or major corporate actions, but rather serves as a routine update. For investors, this filing simply reaffirms the company's compliance with SEC reporting requirements, indicating business as usual without any immediate catalysts or red flags.

Why It Matters

This filing is a standard regulatory update, confirming Genelux's listing on Nasdaq and its compliance with SEC rules. It signals operational stability rather than any significant new developments for investors.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material information that would introduce significant risk.

Analyst Insight

Investors should view this as a routine compliance filing, not an indicator for immediate action. It provides no new material information to alter investment decisions.

Key Numbers

  • $0.001 — Par value per share (The stated par value of Genelux Corporation's common stock.)

Key Players & Entities

  • Genelux Corporation (company) — the registrant filing the 8-K
  • The Nasdaq Stock Market LLC (company) — the exchange where Genelux's common stock is registered
  • GNLX (other) — trading symbol for Genelux Corporation
  • February 5, 2024 (date) — date of earliest event reported and filing date
  • $0.001 (dollar_amount) — par value per share of common stock

FAQ

What is the primary purpose of this 8-K filing by Genelux Corporation?

The primary purpose of this 8-K filing is to provide a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, disclosing general corporate information and confirming its registration on The Nasdaq Stock Market LLC.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 5, 2024.

What is the trading symbol for Genelux Corporation's common stock?

The trading symbol for Genelux Corporation's common stock is GNLX, and it is registered on The Nasdaq Stock Market LLC.

What is the par value per share of Genelux Corporation's common stock?

The par value per share of Genelux Corporation's common stock is $0.001.

Where is Genelux Corporation's principal executive office located?

Genelux Corporation's principal executive office is located at 2625 Townsgate Road, Suite 230, Westlake Village, California, 91361.

Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-02-05 09:15:21

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share GNLX The Nasdaq Stock Mar

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelux Corporation Date: February 5, 2024 By: /s/ Thomas Zindrick, J.D. Thomas Zindrick, J.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.